KELLY MCCARTY: Open Payments
NPI 1821619370 · FAYETTEVILLE, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,112 in 41 payments from 13 companies in 2025. Trend: 2023 $1,080 · 2024 $978 · 2025 $1,112
Food & beverage: $1,112
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 2 | $176 |
| ABBVIE INC. | 11 | $173 |
| Janssen Pharmaceuticals, Inc | 3 | $165 |
| Alkermes, Inc. | 5 | $154 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $106 |
| E.R. Squibb & Sons, L.L.C. | 4 | $88 |
| Vanda Pharmaceuticals Inc. | 2 | $66 |
| Otsuka America Pharmaceutical, Inc. | 2 | $47 |
| Axsome Therapeutics, Inc. | 2 | $34 |
| Indivior Inc. | 2 | $34 |
Products named: INGREZZA, VRAYLAR, SPRAVATO, ARISTADA, CAPLYTA, COBENFY, REXULTI, HETLIOZ.
Industry payments across AR — which companies pay providers there.
